HPVPro Study: Comparison of HPV Detection in Clinician-collected Cervical Swabs and Self-sampled Cervicovaginal Swabs
Launched by THE INSTITUTE OF MOLECULAR AND TRANSLATIONAL MEDICINE, CZECH REPUBLIC · Oct 18, 2019
Trial Information
Current as of July 16, 2025
Completed
Keywords
ClinConnect Summary
The cervical screening program in the Czech Republic is based on cytology with HPV triage. Nevertheless, cytology-based cervical screening may switch to HPV-based cervical screening in future. The implementation of primary HPV screening and insuficiency cervical screening attendance are a major challenge. The offering of self-sampling to the cervical screening non-attenders could increase women's participation as was shown in several European countries. The objective of the HPVPro study was to find out the HPV prevalence in the screening population of Czech women since there are no data for...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women with age 30-64 years.
- • Women attending cervical cancer screening program in Czech Republic.
- • Women with completed informed consent.
- Exclusion Criteria:
- • Pregnant women.
- • Women with no sexual intercourse experience.
- • Women after cervical conization or hysterectomy.
- • Women with CIN or cervical carcinoma in anamnesis.
- • Women at risk of increased bleeding.
About The Institute Of Molecular And Translational Medicine, Czech Republic
The Institute of Molecular and Translational Medicine (IMTM) in the Czech Republic is a leading research institution dedicated to advancing the fields of molecular biology and translational medicine. With a focus on bridging the gap between laboratory research and clinical applications, IMTM aims to develop innovative therapeutic strategies and improve patient outcomes. The institute fosters a collaborative environment that brings together experts in various disciplines, including genetics, pharmacology, and clinical research, to drive scientific discovery and facilitate the translation of findings into practical medical solutions. Through rigorous clinical trials and a commitment to ethical research practices, IMTM is at the forefront of enhancing healthcare and addressing unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Frýdek Místek, , Czechia
Havířov, , Czechia
Olomouc, , Czechia
Patients applied
Trial Officials
Marian Hajduch, MD, PhD.
Study Director
Palacky University in Olomouc, Faculty of Medicine and Dentistry
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials